Currently, many off-the-shelf chimeric antigen receptor (CAR)-T cell products are under investigation for the treatment of relapsed or refractory (R/R) B-cell neoplasms. Compared with autologous CAR-T cell therapy, off-the-shelf universal CAR-T cell therapies have many potential benefits, such as immediate accessibility for patients, stable quality due to industrialized manufacturing and additional infusions of CAR-T cells with different targets. However, critical challenges, including graft-versus-host disease and CAR-T cell elimination by the host immune system, still require extensive research. The most common technological approaches involve modifying healthy donor T cells via gene editing technology and altering different types of T cells. This article summarizes some of the latest data from preclinical and clinical studies of off-the-shelf CAR-T cell therapies in the treatment of R/R B-cell malignancies from the 2023 ASH Annual Meeting (ASH 2023).

中文翻译：

---

用于复发或难治性 B 细胞恶性肿瘤的现成 CAR-T 细胞疗法：ASH 2023 年会的最新进展


目前，许多现成的嵌合抗原受体 （CAR）-T 细胞产品正在研究中，用于治疗复发或难治性 （R/R） B 细胞肿瘤。与自体 CAR-T 细胞疗法相比，现成的通用 CAR-T 细胞疗法具有许多潜在优势，例如患者可立即获得、工业化生产带来的质量稳定以及额外输注具有不同靶点的 CAR-T 细胞。然而，关键挑战，包括移植物抗宿主病和宿主免疫系统消除 CAR-T 细胞，仍然需要广泛的研究。最常见的技术方法包括通过基因编辑技术修饰健康的供体 T 细胞和改变不同类型的 T 细胞。本文总结了 2023 年 ASH 年会 （ASH 2023） 上现成的 CAR-T 细胞疗法治疗 R/R B 细胞恶性肿瘤的临床前和临床研究的一些最新数据。